About Orbit Biomedical
Orbit Biomedical is a Healthcare company based in Ambler (United States) founded in 2018, and was acquired by Gyroscope in April 2019. Medical device for ophthalmic surgery is developed. Orbit Biomedical has raised $12 million across 1 funding round from investors including Syncona and Novartis. The company was acqui-hired. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Alcon, Sight Sciences and Iantrek; 3 of its 3 listed competitors have raised funding.
Company details
Orbit Biomedical was founded in 2018 and is headquartered in Ambler, United States. Operations center on the biomedical sector, where a specialized medical device is developed for ophthalmic surgery. This device enables delivery of one-time therapies to the subretinal space, targeting blinding eye diseases. Access to the subretinal space is achieved without vitrectomy or retinal piercing, supporting minimally invasive procedures in eye care.
- Headquarters Ambler, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website orbitbiomedical.com
- Social LinkedIn
- Acquired by Gyroscope (Apr 2019)
Funding Insights of Orbit Biomedical
Orbit Biomedical has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series A round of $12 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12M
- Total Rounds 1
- Last Round Series A — $12M
- First Round $12M
(Jun 2018)
- Investors Count 1
All 1 funding rounds of Orbit Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $12M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Orbit Biomedical
Orbit Biomedical has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Syncona and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Gene therapies for eye diseases, focusing on AMD, are developed. | 2016 | gyroscopetx.com | Stevenage, United Kingdom |
Investor details for Orbit Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orbit Biomedical
32 people are tracked at Orbit Biomedical (9 in leadership, 9 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Edward Lang Jr | Chief Business Officer | Leadership |
Claire Harris | VP Head Of Biology, Translational Research | Leadership |
Charmaine O'Neill | Associate Director Clinical Operations | Leadership |
Lisa Giles | Head Of Pipeline & Portfolio Strategy | Leadership |
Erin Loken | Associate Director Clinical Operations | Leadership |
Jenny Dines | Director Of People (rest Of World) | Leadership |
Matthew Enos | Associate Clinical Development Director | Pipeline Medical Team | Leadership |
Mari-Lou Biancarelli | Executive Director Of People | Leadership |
Rachel Sartaj | Associate Clinical Development Director | Leadership |
Wouter Joustra | Board Member | Board & advisors |
Maha Katabi | Board Member | Board & advisors |
Chris Hollowood | Chair | Board & advisors |
Anthony Adamis | Board Member | Board & advisors |
Sean Bohen | Board Member | Board & advisors |
Ian Clark | Board Member | Board & advisors |
Jennifer Cook | Board Member | Board & advisors |
David Fellows | Board Member | Board & advisors |
Renée Galá | Board Member | Board & advisors |
Sam Reichenbacker | Surgical Lab Coordinator | Team |
Sebastián Handorf | Senior Manager, Clinical Contracts | Team |
12 more people are available in the full profile.
Complete people profiles for Orbit Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orbit Biomedical
3 dated milestones of Orbit Biomedical across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Orbit Biomedical is founded.
- Funding First funding round of $12.0M.
- Exit Acquired by Gyroscope.
Competitors of Orbit Biomedical
Orbit Biomedical has 3 listed competitors in our database, 3 of them funded. They include Alcon, Sight Sciences and Iantrek.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alcon.com | 1945 | Fort Worth, United States | $171.61M | 25,315 | Developer of a wide range of eye care products | |
| sightsciences.com | 2006 | Menlo Park, United States | $128.59M | 204 | Surgical systems for ophthalmological disease treatment are developed. | |
| iantrekmed.com | 2019 | White Plains, United States | $67.78M | 2 | Developer of a minimally invasive eye surgery technology |
Detailed competitors of Orbit Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Orbit Biomedical (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orbit Biomedical
Complete news archive for Orbit Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orbit Biomedical
Orbit Biomedical was founded in 2018.
Orbit Biomedical is headquartered in Ambler, United States. It is registered at Ambler, Pennsylvania, United States.
Orbit Biomedical is a funded company, having raised a total of $12M across 1 funding round to date. The company's 1st funding round was a Series A of $12M, raised on Jun 2018.
Orbit Biomedical was founded in 2018 and is headquartered in Ambler, United States. Operations center on the biomedical sector, where a specialized medical device is developed for ophthalmic surgery. This device enables delivery of one-time therapies to the subretinal space, targeting blinding eye diseases. Access to the subretinal space is achieved without vitrectomy or retinal piercing, supporting minimally invasive procedures in eye care.
Orbit Biomedical's top competitors include Alcon, Sight Sciences and Iantrek.
Yes. Orbit Biomedical was acquired by Gyroscope in April 2019.